A new contender has emerged in the domain of pain-focused biotechnology, marking...
Denali and Sanofi have been working together since 2018, when they reached an ag...
In a chain of unfolding events reminiscent of the tumbling of dominos, Gilead Sc...
The U.S. Food and Drug Administration (FDA) has given the green light to Eohilia...
Gritstone Bio has secured a substantial sum of $433 million in federal funding e...
LianBio, a significant player in the biotech industry based in Shanghai, has rec...
CSL Behring, a prominent player in the Australian pharmaceutical landscape, rece...
In November, regulators overseeing pharmaceutical standards in the U.S. identifi...
Gilead Sciences has agreed to purchase CymaBay Therapeutics for $4.3 billion, ai...
Unlearn, a developer specializing in digital replicas, recently disclosed its at...
Johnson & Johnson’s recent triumph with its $6.5 billion autoimmune medication i...
The recent buzz surrounding a potential bidding war for the cancer specialist Mo...
A Chinese biotechnology company’s experimental gene therapy has demonstrated enc...
In an unforeseen development, the FDA’s directive for a labeling alteration conc...
Novo Nordisk has announced its highest annual profit in decades, attributing it ...
Defender Pharmaceuticals, headquartered in St. Louis, faces a setback in its que...
